


Amendments to the Claims:

Please cancel claims 19 and 26 and add new claims 43-54. Please amend claims 1-18, 20-21, 23-25, and 42 as follows.

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Currently amended) A compound of Formula (I):



or pharmaceutically acceptable salt thereof, wherein:

R¹ is H or C₁-C₃ alkyl;

R² is C₁-C₄ alkyl;

R³ is H, arylalkyl-O-, arylalkyl-N(R⁵)-, aryl-N(R⁵)-, or heteroaryl; or

R² is [(H,)aryl, arylalkyl-O-, arylalkyl-N(R⁵)-, aryl-N(R⁵)-, or heteroaryl], wherein said aryl which is optionally substituted with up to two substituents selected from C₁₋₃ alkyl, halogen, perhaloalkyl, and alkoxy;

R⁴ is H, arylalkyl-O-, alkoxy, or aryloxy; and

R⁵ is H, C₁-C₃ alkyl, aryl, C₁₋₄ alkenyl C₂₋₃ alkenyl, heteroaryl, arylalkyl, heteroarylalkyl, perhaloalkyl, or allyl;

with the provisos:

a) at least one of R³ and R⁴ is other than H;

b) when R² is arylalkyl-N(R⁵)- or aryl-N(R⁵)- and R⁴ is H, then R¹ is H;

- c) when R¹ is H, R² is CH₃ and R³ is 2-chlorophenyl, then R⁴ is other than H; and
- d) when R¹ is H, R² is CH₃ and R³ is 2-thienyl, then R⁴ is other than methoxy.

2. (Currently amended) The compound of claim 1, or pharmaceutically acceptable salt thereof, wherein:

R¹ is H or C₁-C₆ alkyl;


R² is C₁-C₆ alkyl;

R³ is H, aryl, arylalkyl-O-, arylalkyl-N(R⁵)-, or aryl-N(R⁵)- wherein said aryl is optionally substituted with up to two substituents selected from C₁₋₄ alkyl, halogen, perhaloalkyl, and alkoxy;

R⁴ is H or aryloxy; and


R⁵ is H, C₁-C₆ alkyl, aryl, C₄₋₆ alkenyl C₂₋₃ alkenyl, heteroaryl, arylalkyl, heteroarylalkyl, perhaloalkyl, or allyl.

3. (Currently amended) A compound of claim 1, or pharmaceutically acceptable salt thereof, having Formula (Ia):



or pharmaceutically acceptable salt form thereof.

4. (Currently amended) A compound of claim 1, or pharmaceutically acceptable salt thereof, having Formula (Ib):



or pharmaceutically acceptable salt form thereof.

5. (Currently amended) The compound of claim 1, or pharmaceutically acceptable salt thereof, wherein:

R¹ is H or C₁-C₈ alkyl;
R² is C₁-C₈ alkyl;
R³ is arylalkyl-O-, arylalkyl-N(R⁵)-, or aryl-N(R⁵)-;
R⁴ is H; and
R⁵ is H, C₁-C₈ alkyl, aryl, C₄₋₈ alkenyl, C₂₋₈ alkenyl, heteroaryl, arylalkyl, heteroarylalkyl, perhaloalkyl, or allyl.

6. (Currently amended) The compound of claim 1, or pharmaceutically acceptable salt thereof, wherein:

R¹ is H or C₁-C₈ alkyl;
R² is C₁-C₈ alkyl;
R³ is arylalkyl-O-, arylalkyl-N(R⁵)-, or aryl-N(R⁵)-;
R⁴ is H; and
R⁵ is H, C₁-C₈ alkyl, or aryl.

7. (Currently amended) The compound of claim 1, or pharmaceutically acceptable salt thereof, wherein:

R¹ is H or C₁-C₈ alkyl;
R² is C₁-C₈ alkyl;
R³ is arylalkyl-O-; and
R⁴ is H.

8. (Currently amended) The compound of claim 1, or pharmaceutically acceptable salt thereof, wherein:

R¹ is H or C₁-C₈ alkyl;
R² is C₁-C₈ alkyl;
R³ is H; and
R⁴ is arylalkyl-O-.

9. (Currently amended) The compound of claim 1, or pharmaceutically acceptable salt thereof, wherein:

R¹ is H;
R² is C₁-C₄ alkyl;
R³ is arylalkyl-O-; and
R⁴ is H.

10. (Currently amended) The compound of claim 1, or pharmaceutically acceptable salt thereof, wherein:

R¹ is H;
R² is C₁-C₈ alkyl;
R³ is arylalkyl-N(R⁵)-;
R⁴ is H; and
R⁵ is H, C₁-C₈ alkyl, or aryl.

11. (Currently amended) The compound of claim 1, or pharmaceutically acceptable salt thereof, wherein:

R¹ is H;
R² is methyl;
R³ is phenyl, phenylalkyl-O-, phenylalkyl-N(R⁵)-, or phenyl-N(R⁵)-;
R⁴ is H; and
R⁵ is H.

12. (Currently amended) The compound of claim 1, or pharmaceutically acceptable salt thereof, wherein:

R¹ is H;
R² is methyl;
R³ is H; and
R⁴ is phenylalkyl-O-.

13. (Currently amended) The compound of claim 1, or pharmaceutically acceptable salt thereof, wherein:

R¹ is H;

R² is methyl;

R³ is phenyl optionally substituted with up to two halogens, or R³ is pyridinyl; and

R⁴ is H or alkoxy.

14. (Currently amended) The compound of claim 1, or pharmaceutically acceptable salt thereof, wherein:

R¹ is H;

R² is methyl;

R³ is phenyl optionally substituted with up to two fluoro; and

R⁴ is H or methoxy.

15. (Currently amended) The compound of claim 1, or pharmaceutically acceptable salt thereof, wherein:

R¹ is H;

R² is methyl;

R³ is pyridinyl; and

R⁴ is H.

16. (Currently amended) A compound of any one of claims 1 to 4 claim 1, selected from:

- a) 7-benzyloxy-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;
- b) 1-methyl-7-(1-phenyl-ethoxy)-2,3,4,5-tetrahydro-1H-benzo[d]azepine;
- c) 1-methyl-7-phenethoxy-2,3,4,5-tetrahydro-1H-benzo[d]azepine;
- d) 1-methyl-7-(3-phenyl-propoxy)-2,3,4,5-tetrahydro-1H-benzo[d]azepine;
- e) benzyl-(5-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)-amine;
- f) (5-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)-(1'-phenyl-ethyl)-amine;
- g) benzyl-methyl-(5-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)-amine;
- h) (5-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)-phenethyl-amine;
- i) (5-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)-(3-phenyl-propyl)-amine;

- j) (5-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)-phenyl-amine; and
k) 1-methyl-8-phenyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;
or pharmaceutically acceptable salt thereof.
17. (Currently amended) A compound of any one of claims 1 to 4 claim 1, selected from:
 - a) 8-Benzylxylo-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;
 - b) 7-Benzylxylo-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;
 - c) 1-Methyl-8-phenyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;
 - d) 7-Methoxy-1-methyl-8-phenyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;
 - e) 8-(2-Fluoro-phenyl)-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;
 - f) 8-(3-Fluoro-phenyl)-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;
 - g) 8-(4-Fluoro-phenyl)-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;
 - h) 8-(2,6-Difluoro-phenyl)-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;
 - i) 8-(2,3-Difluoro-phenyl)-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;
 - j) 8-(2,5-Difluoro-phenyl)-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;
 - k) 1-Methyl-8-pyridin-3-yl-2,3,4,5-tetrahydro-1H-benzo[d]azepine; and
l) 1-Methyl-8-pyridin-2-yl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;
or pharmaceutically acceptable salt thereof.
18. (Currently amended) A composition comprising a compound of claim 1, or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
19. (Canceled)
20. (Currently amended) A method of treating a disorder The method of claim 19 wherein the disorders of the central nervous system are selected from depression, atypical depression, bipolar disorders, anxiety disorders, obsessive-compulsive disorder[[s]], social phobia[[s or]], panic states, sleep-disorders, sexual dysfunction, psychoses, schizophrenia, migraine and other conditions associated with cephalic pain or other pain, raised intracranial pressure, epilepsy, personality disorders, age related behavioral disorders, behavioral disorders associated with

dementia, organic mental disorders, mental disorders in childhood, aggressivity, age-related memory disorders, chronic fatigue syndrome, drug and alcohol addiction, and obesity, bulimia, anorexia-nervosa and premenstrual tension comprising administering to a patient in need of said treating a therapeutically effective amount of a compound of claim 1, or pharmaceutically acceptable salt thereof.

21. (Currently amended) The method according to claim 19 wherein the disorder of the central nervous system is obesity.
22. (Original) The method according to claim 19 wherein the sexual dysfunction is male erectile dysfunction.
23. (Currently amended) A method of decreasing food intake of a mammal comprising administering to said mammal a therapeutically effective amount of a compound of claim 1, or pharmaceutically acceptable salt thereof.
24. (Currently amended) A method of inducing satiety in a mammal comprising administering to said mammal a therapeutically effective amount of a compound of claim 1, or pharmaceutically acceptable salt thereof.
25. (Currently amended) A method of controlling weight gain of a mammal comprising administering to said mammal a therapeutically effective amount of a compound of claim 1, or pharmaceutically acceptable salt thereof.
- 26-41. (Cancelled)
42. (Currently amended) A method for preparing a pharmaceutical composition comprising the step of mixing a compounds of claim 1, or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

43. (New) The method according to claim 19 wherein the disorder is depression.
44. (New) The method according to claim 19 wherein the disorder is anxiety.
45. (New) The method according to claim 19 wherein the disorder is obsessive-compulsive disorder.
46. (New) The method according to claim 19 wherein the disorder is social phobia.
47. (New) The method according to claim 19 wherein the disorder is panic states.
48. (New) The method according to claim 19 wherein the disorder is psychoses.
49. (New) The method according to claim 19 wherein the disorder is schizophrenia.
50. (New) The method according to claim 19 wherein the disorder is selected from drug and alcohol addiction.
51. (New) A compound of claim 1 selected from:
 - a) (R)-7-benzyloxy-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;
 - b) (R)-1-methyl-7-(1-phenyl-ethoxy)-2,3,4,5-tetrahydro-1H-benzo[d]azepine;
 - c) (R)-1-methyl-7-phenethoxy-2,3,4,5-tetrahydro-1H-benzo[d]azepine;
 - d) (R)-1-methyl-7-(3-phenyl-propoxy)-2,3,4,5-tetrahydro-1H-benzo[d]azepine;
 - e) (R)-benzyl-(5-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)-amine;
 - f) (R)-(5-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)-(1'-phenyl-ethyl)-amine;
 - g) (R)-benzyl-methyl-(5-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)-amine;
 - h) (R)-(5-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)-phenethyl-amine;
 - i) (R)-(5-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)-(3-phenyl-propyl)-amine;
 - j) (R)-(5-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)-phenyl-amine; and
 - k) (R)-1-methyl-8-phenyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;or pharmaceutically acceptable salt thereof.

52. (New) A compound of claim 1 selected from:

- a) (S)-7-benzyloxy-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;
- b) (S)-1-methyl-7-(1-phenyl-ethoxy)-2,3,4,5-tetrahydro-1H-benzo[d]azepine;
- c) (S)-1-methyl-7-phenethyloxy-2,3,4,5-tetrahydro-1H-benzo[d]azepine;
- d) (S)-1-methyl-7-(3-phenyl-propoxy)-2,3,4,5-tetrahydro-1H-benzo[d]azepine;
- e) (S)-benzyl-(5-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)-amine;
- f) (S)- (5-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)-(1'-phenyl-ethyl)-amine;
- g) (S)-benzyl-methyl-(5-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)-amine;
- h) (S)-(5-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)-phenethyl-amine;
- i) (S)-(5-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)-(3-phenyl-propyl)-amine;
- j) (S)-(5-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)-phenyl-amine; and
- k) (S)-1-methyl-8-phenyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

or pharmaceutically acceptable salt thereof.

53. (New) A compound of claim 1 selected from:

- a) (R)-8-Benzyl-oxo-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;
- b) (R)-7-Benzyl-oxo-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;
- c) (R)-1-Methyl-8-phenyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;
- d) (R)-7-Methoxy-1-methyl-8-phenyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;
- e) (R)-8-(2-Fluoro-phenyl)-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;
- f) (R)-8-(3-Fluoro-phenyl)-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;
- g) (R)-8-(4-Fluoro-phenyl)-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;
- h) (R)-8-(2,6-Difluoro-phenyl)-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;
- i) (R)-8-(2,3-Difluoro-phenyl)-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;
- j) (R)-8-(2,5-Difluoro-phenyl)-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;
- k) (R)-1-Methyl-8-pyridin-3-yl-2,3,4,5-tetrahydro-1H-benzo[d]azepine; and
- l) (R)-1-Methyl-8-pyridin-2-yl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

or pharmaceutically acceptable salt thereof.

54. (New) A compound of claim 1 selected from:

- a) (S)-8-Benzyl-oxo-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

- b) (S)-7-Benzyl-8-phenyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;
- c) (S)-1-Methyl-8-phenyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;
- d) (S)-7-Methoxy-1-methyl-8-phenyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;
- e) (S)-8-(2-Fluoro-phenyl)-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;
- f) (S)-8-(3-Fluoro-phenyl)-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;
- g) (S)-8-(4-Fluoro-phenyl)-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;
- h) (S)-8-(2,6-Difluoro-phenyl)-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;
- i) (S)-8-(2,3-Difluoro-phenyl)-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;
- j) (S)-8-(2,5-Difluoro-phenyl)-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine; and
- l) (S)-1-Methyl-8-pyridin-3-yl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

or pharmaceutically acceptable salt thereof.